Immatics' Promising Immunotherapy Developments Bolster Jonathan Chang's Buy Rating
Immatics Unveils Promising TCR-T Therapy Developments
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Positive Outlook for Immatics Due to Promising Clinical Trial Results and Manageable Safety Profiles
Piper Sandler Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $19
Analysts Conflicted on These Healthcare Names: AnaptysBio (ANAB), Stoke Therapeutics (STOK) and Immatics (IMTX)